Image-Guided Percutaneous 125I Seed Implantation As a Salvage Treatment for Recurrent Soft Tissue Sarcomas after Surgery and Radiotherapy
Jinna Li,Junjie Wang,Na Meng,Ang Qu,Huishu Yuan,Chen Liu,Weiqiang Ran,Yuliang Jiang
DOI: https://doi.org/10.1089/cbr.2010.0847
2011-01-01
Cancer Biotherapy and Radiopharmaceuticals
Abstract:The purpose of this study was to evaluate the safety and efficacy of percutaneous iodine-125 (I-125) seed implantation using computed tomography (CT) or ultrasound guidance in the treatment of recurrent soft tissue malignancies after surgery and radiotherapy. From February 2002 to September 2009, 18 patients with recurrent soft tissue sarcomas were treated under ultrasound or CT guidance. The actuarial median number of I-125 seeds implanted was 35 (range, 6-129), and the actuarial D90 of the implanted I-125 seeds ranged from 107.9 to 204.4 Gy (median, 147.1 Gy). The activity of the seeds ranged from 0.4 to 0.8 mCi (median, 0.7mCi). Follow-up times ranged from 4 to 78 months (median, 20 months). The median local control was 41 months (95% CI, 15.9-66.1 months). The 1-, 2-, 3-, 4-, and 5-year local controls were 78.8%, 78.8%, 78.8%, 26.3%, and 0%, respectively. The median survival was 32 months (95% CI, 16-48 months). The actuarial 1-, 2-, 3-, 4-, and 5-year survivals were 76.6%, 61.3%, 39.4%, 39.4%, and 39.4%, respectively. Seven (7) patients (38.9%) experienced recurrence after seed implantation. Six (6) patients (33.3%) died of distant metastases and 1 died of stroke. Two (2) patients developed ulceration, 1 case caused by recurrence and another by a reaction of the skin to radiation. Percutaneous I-125 seed implantation for recurrent soft tissue malignancies under CT or ultrasound guidance is safe and is associated with high efficacy and low morbidity.